scholarly journals Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protege Trial

Diabetes ◽  
2013 ◽  
Vol 62 (11) ◽  
pp. 3901-3908 ◽  
Author(s):  
W. Hagopian ◽  
R. J. Ferry ◽  
N. Sherry ◽  
D. Carlin ◽  
E. Bonvini ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
C Peptide ◽  
Recent Onset ◽  
Onset Type

scholarly journals A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Alpha-1 Antitrypsin (AAT) (Glassia®) in the Treatment of Recent-Onset Type 1 Diabetes

2019 ◽  
Vol 20 (23) ◽  
pp. 6032 ◽  
Author(s):  
Lebenthal ◽  
Brener ◽  
Hershkovitz ◽  
Shehadeh ◽  
Shalitin ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Therapeutic Modality ◽  
Β Cell ◽  
C Peptide ◽  
Recent Onset ◽  
Onset Type ◽  
Alpha 1 Antitrypsin ◽  
The Impact ◽  
Cell Preservation

Our aim was to assess the efficacy, safety, and tolerability of alpha-1 antitrypsin (AAT) as a therapeutic modality for β-cell preservation in patients with recent-onset type 1 diabetes. Seventy type 1 diabetes patients (37 males; mean age 13.1 ± 4.1years) were randomized to treatment with 22 infusions of AAT (Glassia®) (60 or 120 mg/kg) or placebo. The primary outcome was the area under the curve (AUC) of C-peptide from a 2-h mixed-meal tolerance test after 52 weeks. At week 52, C-peptide was 0.9, 0.45, and 0.48 pmol/mL in the AAT-120, AAT-60, and placebo groups (p = 0.170 and p = 0.866 vs. placebo, respectively). The declines in C-peptide glycated hemoglobin (HbA1c) and the total insulin dose (U/kg) were similar across groups. Within the predefined 12–18-years subgroup, the C-peptide AUC decreased significantly in the placebo and AAT-60 groups (−0.34 and −0.54 pmol/mL, respectively, p < 0.01), with a borderline decrease in the AAT-120 group (−0.29 pmol/mL, p = 0.047). The mean HbA1c level was significantly lower in the AAT-120 group compared to the placebo (6.7% ± 0.9% vs. 8.2 ± 1.4%, p = 0.05), and a higher percentage of patients attained HbA1c ≤ 7% (75% vs. 25%, p = 0.05). AAT was tolerated well, with a similar safety profile between groups. The AAT intervention showed promise in the subgroup of adolescents with recent-onset type 1 diabetes. Further studies are warranted to determine the impact and proposed mechanism of action of AAT in β-cell preservation.

scholarly journals C-Peptide Response and HLA Genotypes in Subjects With Recent-Onset Type 1 Diabetes After Immunotherapy With DiaPep277

Diabetes ◽  
2011 ◽  
Vol 60 (11) ◽  
pp. 3067-3072 ◽  
Author(s):  
Raffaella Buzzetti ◽  
Simona Cernea ◽  
Antonio Petrone ◽  
Marco Capizzi ◽  
Marialuisa Spoletini ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
C Peptide ◽  
Recent Onset ◽  
Onset Type ◽  
Hla Genotypes

scholarly journals A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX)

2004 ◽  
pp. 719-724 ◽  
Author(s):  
A Crino ◽  
R Schiaffini ◽  
S Manfrini ◽  
C Mesturino ◽  
N Visalli ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Vitamin E ◽  
Insulin Therapy ◽  
Intensive Insulin Therapy ◽  
Cell Function ◽  
C Peptide ◽  
Recent Onset ◽  
Onset Type ◽  
Peptide Secretion

OBJECTIVE: Various adjuvant therapies have been introduced along with intensive insulin therapy in patients with recent onset type 1 diabetes. Nicotinamide (NA), administered at diagnosis of the disease, can have beneficial effects on the clinical remission rate, improve metabolic control and preserve or slightly increase beta-cell function, probably by reducing toxicity due to free oxygen radicals. Vitamin E, a known antioxidant, inhibits lipid peroxidation; this can lead to protection of islet beta cells from the combined effects of interleukin 1, tumor necrosis factor and gamma interferon. The aim of the present study was to investigate whether the addition of vitamin E to NA could improve metabolic control and the residual beta-cell function, as measured by C-peptide secretion, in children and adolescents with recent onset type 1 diabetes; patients were followed-up for 2 years after diagnosis. PATIENTS AND STUDY DESIGN: Recent onset type 1 diabetes patients (n=64, mean age 8.8 years) were recruited by participating centres of the IMDIAB group. Thirty-two patients were randomized to NA (25 mg/kg body weight) plus vitamin E (15 mg/kg body weight); 32 patients acted as controls and received NA only at the same dose as above. Intensive insulin therapy was applied to both treatment groups. RESULTS: There were three drop outs during the 2-year follow-up period. Overall, patients assigned to the NA+vitamin E group or the NA group did not significantly differ in terms of glycated hemoglobin (HbA1c) levels, insulin requirement or baseline C-peptide secretion. Patients diagnosed at an age of less than 9 years showed significantly reduced C-peptide levels compared with those aged over 9 years at diagnosis and at the 2-year follow-up but there were no differences between the NA and NA+vitamin E treated groups. However at 6 months, patients over 9 years of age treated with NA+vitamin E showed significantly higher C-peptide compared with the NA group (P<0.003). In both age groups and in the different treatment groups, C-peptide levels found at diagnosis were preserved 2 years later. CONCLUSIONS: The use of NA alone, or in combination with vitamin E, along with intensive insulin therapy is able to preserve baseline C-peptide secretion for up to 2 years after diagnosis. This finding is of particular interest for pre-pubertal children with type 1 diabetes and has never been reported before.

scholarly journals Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes

Diabetologia ◽  
2020 ◽  
Vol 63 (10) ◽  
pp. 2177-2181 ◽  
Author(s):  
Ulf Hannelius ◽  
Craig A. Beam ◽  
Johnny Ludvigsson
Keyword(s):  
Type 1 Diabetes ◽  
Treatment Effect ◽  
Repeated Measures ◽  
C Peptide ◽  
Recent Onset ◽  
Individual Level ◽  
Onset Type ◽  
Hla Dr3 ◽  
Effect Ratio

Abstract Aims/hypothesis The aim of this study was to determine if retention of C-peptide following immunotherapy using recombinant GAD65 conjugated to aluminium hydroxide (GAD-alum) is influenced by HLA risk haplotypes DR3-DQ2 and DR4-DQ8. Methods HLA-dependent treatment effect of GAD-alum therapy on C-peptide retention in individuals with recent-onset type 1 diabetes was evaluated using individual-level patient data from three placebo-controlled, randomised clinical trials using a mixed repeated measures model. Results A significant and dose-dependent effect was observed in individuals positive for the genotypes that include HLA-DR3-DQ2 but not HLA-DR4-DQ8 and in the broader subgroup of individuals positive for all genotypes that include HLA-DR3-DQ2 (i.e. including those also positive for HLA-DR4-DQ8). Higher doses (three or four injections) showed a treatment effect ratio of 1.596 (95% CI 1.132, 2.249; adjusted p = 0.0035) and 1.441 (95% CI 1.188, 1.749; adjusted p = 0.0007) vs placebo for the two respective HLA subgroups. Conclusions/interpretation GAD65-specific immunotherapy has a significant effect on C-peptide retention in individuals with recent-onset type 1 diabetes who have the DR3-DQ2 haplotype.

scholarly journals An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes

2019 ◽  
Vol 20 (2) ◽  
pp. 166-171 ◽  
Author(s):  
Kerry Buchanan ◽  
Ahmed M Mehdi ◽  
Ian Hughes ◽  
Andrew Cotterill ◽  
Kim-Anh Le Cao ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
C Peptide ◽  
Clinical Model ◽  
Recent Onset ◽  
Onset Type

Nicotinamide Increases C-peptide Secretion in Patients with Recent Onset Type 1 Diabetes

1989 ◽  
Vol 6 (7) ◽  
pp. 568-572 ◽  
Author(s):  
P. Pozzilli ◽  
N. Visalli ◽  
G. Ghirlanda ◽  
R. Manna ◽  
D. Andreani
Keyword(s):  
Type 1 Diabetes ◽  
C Peptide ◽  
Recent Onset ◽  
Onset Type ◽  
Peptide Secretion
Sign in / Sign up

Export Citation Format

Share Document